Contact us for help with your samples

Metabolomics

LECO’s high-resolution mass spectrometry and GC×GC platforms provide comprehensive metabolite profiling, helping researchers discover biomarkers, understand disease, and analyze complex biological samples.

2012-press-leco-berkeley

LECO and Berkeley Lab Partner for Metabolomics Advancements

209-207

LECO-Fiehn Metabolomics Library

ext-slides-abdi-lipids

Lipid Analysis with Differential Mobility Spectrometry

209-240

Market Brochure: Metabolomics

JH-ASMS09-LPSS-007

Metabolic Biomarkers from Diabetic and Non-Diabetic Urine Fisher Ratios GCxGC-TOFMS

JH-ASMS11-LPSS-040

Metabolite Differences Lean Fat Obese Zucker Rat Plasma GCxGC-TOFMS

CK-GCC18-LPSS-292

Metabolite Profiling Type-2 Diabetes Patient Plasma

JP-ASMS00-LPSS-151

Metabolites EI-CI GC-HRT

JP-ASMS14-LPSS-153

Metabolites Medicago Truncatula GC-HRT

DA-IMSC16-LPSS-200

Metabolomic Analysis of Human Urine through GC-TOFMS

A workflow for metabolomic analysis of human urine samples is explored.
203-821-526

Metabolomic Profiling of Corn and Rice Extracts Using a Benchtop GC-TOFMS

DA-RIVA14-LPSS-132

Metabolomic Studies GC-GC-HRT-TOFMS

209-232-003

Metabolomics Articles and References

HF-PCON13-LPSS-100

Metabolomics Brain Injury GCxGC-TOFMS

DA-ASMS13-LPSS-124

Metabolomics Data Acquisition Workflow EI-CI HRT

Metabolomics in Agricultural Research

DA-MBX16-LPSS-193

Metabolomics Liver Disease GCxGC-HRT-TOFMS

Metabolomics Questions with Ralf Loscher

Following the recent 15th Annual Conference of the Metabolomic Society in the Hague, Dr Ralf Löscher, Vice President of LECO Europe, answers questions concerning LECO's role as a leader in GC-MS metabolomics, with Separation Science.
JH-ASMS13-LPSS-120

Metabolomics Sample Prep Data Interpretation GC-TOFMS

203-821-733

Modern-day Urinalysis; Combining Enhanced Chromatography with High Resolution Time-of-Flight Mass Spectrometry to Discover Potential Prostate Cancer Biomarkers in Human Urine

Today, urinalysis plays a crucial role in identifying disease-associated biomarkers, particularly for conditions where early detection is crucial. In oncology, urine-based assays are being developed for cancers such as bladder, prostate, kidney, a...